World Investment Advisors lifted its holdings in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 79.2% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,328 shares of the biotechnology company's stock after buying an additional 1,029 shares during the period. World Investment Advisors' holdings in United Therapeutics were worth $718,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of UTHR. Brookstone Capital Management purchased a new position in United Therapeutics in the first quarter valued at approximately $1,479,000. IFM Investors Pty Ltd lifted its stake in United Therapeutics by 5.9% in the first quarter. IFM Investors Pty Ltd now owns 8,682 shares of the biotechnology company's stock valued at $2,676,000 after purchasing an additional 484 shares during the last quarter. GF Fund Management CO. LTD. lifted its stake in United Therapeutics by 22.0% in the first quarter. GF Fund Management CO. LTD. now owns 1,143 shares of the biotechnology company's stock valued at $352,000 after purchasing an additional 206 shares during the last quarter. Principal Financial Group Inc. lifted its stake in United Therapeutics by 0.3% in the first quarter. Principal Financial Group Inc. now owns 111,861 shares of the biotechnology company's stock valued at $34,483,000 after purchasing an additional 309 shares during the last quarter. Finally, Meritage Portfolio Management lifted its stake in United Therapeutics by 5.8% in the first quarter. Meritage Portfolio Management now owns 1,530 shares of the biotechnology company's stock valued at $472,000 after purchasing an additional 84 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.
United Therapeutics Trading Up 0.1%
Shares of United Therapeutics stock traded up $0.44 during trading on Thursday, hitting $301.00. The stock had a trading volume of 87,174 shares, compared to its average volume of 444,507. The firm has a market cap of $13.58 billion, a price-to-earnings ratio of 12.01, a P/E/G ratio of 6.45 and a beta of 0.53. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $417.82. The business's 50-day moving average is $300.90 and its 200 day moving average is $321.20.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping the consensus estimate of $6.29 by $0.34. The firm had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The business's quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $6.17 earnings per share. As a group, equities analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.
Insider Transactions at United Therapeutics
In related news, Director Nilda Mesa sold 645 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total value of $187,043.55. Following the transaction, the director owned 4,883 shares of the company's stock, valued at $1,416,021.17. This represents a 11.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO James Edgemond sold 12,000 shares of United Therapeutics stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $325.37, for a total value of $3,904,440.00. Following the sale, the chief financial officer directly owned 8,118 shares of the company's stock, valued at approximately $2,641,353.66. This trade represents a 59.65% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 76,681 shares of company stock valued at $22,813,739. Corporate insiders own 10.30% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts recently commented on the company. Wall Street Zen downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Morgan Stanley increased their target price on United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 1st. HC Wainwright restated a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research report on Monday, May 5th. JPMorgan Chase & Co. dropped their target price on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research report on Tuesday. Finally, Cantor Fitzgerald began coverage on United Therapeutics in a research report on Monday, June 2nd. They set an "overweight" rating and a $405.00 target price on the stock. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $384.62.
Get Our Latest Stock Report on UTHR
United Therapeutics Company Profile
(
Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Articles

Before you consider United Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.
While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.